Drug Report History

Return to report

Below you will find the report version history. When a report is updated, a new version of the report is created. The report history allows you to see the changes between versions. You can select two versions of the report to compare. The fields that were changed between versions will be highlighted in yellow.

The translation of reports creates two separate versions which is why some reports may not seem to have any differences. In this case, only the language field below will be highlighted in yellow.

Version v11-FR Version v6-EN
Language French English
Date Updated 2018-04-27 2018-04-13
Drug Identification Number 02304341 02304341
Brand name SODIUM CHLORIDE INJECTION USP 0.9% SODIUM CHLORIDE INJECTION USP 0.9%
Common or Proper name Sodium Chloride Injection Sodium Chloride Injection
Company Name HIKMA CANADA LIMITED HIKMA CANADA LIMITED
Ingredients SODIUM CHLORIDE SODIUM CHLORIDE
Strength(s) 9MG 9MG
Dosage form(s) SOLUTION SOLUTION
Route of administration INTRAMUSCULAR INTRAVENOUS SUBCUTANEOUS INTRAMUSCULAR INTRAVENOUS SUBCUTANEOUS
Packaging size 10 ML 10 ML
ATC code V07AB V07AB
ATC description ALL OTHER NON-THERAPEUTIC PRODUCTS ALL OTHER NON-THERAPEUTIC PRODUCTS
Reason for shortage Other (Please describe in comments) Other (Please describe in comments)
Anticipated start date
Actual start date 2018-04-01 2018-04-01
Estimated end date 2018-04-27 2018-05-01
Actual end date 2018-04-26
Shortage status Resolved Actual shortage
Tier 3 Status No No
Company comments - McKesson allocation is in effect as of April 1, 2018. - Teligent HAS AMPLE SUPPLY and is SHIPPING ORDERS EFFECTIVE IMMEDIATELY. - We anticipate removing allocation and moving to regular supply April 27. McKesson allocation in effect as of April 01, 2018. Next expected shipment is April 25. Anticipated to have enough inventory to cover entire Canadian market as of May 1, 2018 with no need for allocations.
Health Canada comments